Definition and epidemiology
Intracerebral hemorrhage is bleeding that occurs directly within the brain parenchyma, as opposed to subarachnoid, subdural, or epidural spaces. It is a subtype of hemorrhagic stroke.
- Accounts for roughly 10-15% of all strokes, with ischemic stroke making up the large majority.
- Carries the highest mortality of all stroke subtypes, with 30-day mortality commonly cited around 30-40%.
- Incidence rises sharply with age and is higher in Asian populations and in Black and Hispanic populations compared with White populations in the US, likely reflecting hypertension prevalence and control.
- P10.1 refers specifically to intracerebral hemorrhage due to birth injury in neonates, a distinct entity from adult spontaneous ICH.
- Noncontrast CT is the test of choice to diagnose ICH and distinguish it from ischemic stroke.
- Hypertensive ICH classically involves the basal ganglia, thalamus, pons, and cerebellum.
- Cerebral amyloid angiopathy causes recurrent lobar hemorrhages in normotensive elderly patients.
- Charcot-Bouchard microaneurysms are the classic pathologic lesion in hypertensive ICH.
- CT angiography 'spot sign' predicts hematoma expansion and worse outcome.
- Target systolic BP around 140 mmHg is a reasonable acute management goal per AHA/ASA guidance.
- Cerebellar hemorrhage with brainstem compression is a neurosurgical emergency.
- Routine early surgery for supratentorial ICH has not shown clear benefit in major trials.
Etiology and risk factors
Primary (spontaneous) ICH
- Hypertensive small vessel disease - the leading cause overall; produces bleeds in deep structures (basal ganglia, thalamus, pons, cerebellum) from rupture of small penetrating arterioles affected by lipohyalinosis and microaneurysm (Charcot-Bouchard) formation.
- Cerebral amyloid angiopathy (CAA) - the leading cause in normotensive elderly patients; amyloid deposition in cortical and leptomeningeal vessel walls leads to lobar hemorrhages, often recurrent.
Secondary ICH
- Anticoagulant or antiplatelet therapy
- Coagulopathy or thrombocytopenia
- Vascular malformations (arteriovenous malformation, cavernous malformation)
- Hemorrhagic transformation of an ischemic infarct
- Cerebral venous sinus thrombosis
- Sympathomimetic drug use (cocaine, amphetamines)
- Brain tumor (primary or metastatic)
- Vasculitis
Risk factors
- Chronic hypertension (the single strongest modifiable risk factor)
- Advanced age
- Excessive alcohol use
- Smoking
- Anticoagulant/antiplatelet use
- Low LDL and statin-related bleeding risk is debated but less significant clinically
Pathophysiology
Chronic hypertension causes degenerative changes in the walls of small penetrating arteries (lipohyalinosis), weakening them and predisposing to formation of microaneurysms, which rupture under hemodynamic stress. This explains the classic deep locations: putamen and basal ganglia (most common), thalamus, pons, and cerebellum.
In CAA, beta-amyloid deposits replace smooth muscle in the media and adventitia of small cortical and leptomeningeal vessels, making them fragile and prone to rupture, producing lobar (cortical-subcortical) hemorrhages typically sparing deep gray structures.
Once bleeding begins, the expanding hematoma causes direct mechanical injury, raises local and then global intracranial pressure, and can trigger mass effect, herniation, and secondary injury from edema, inflammation, and excitotoxicity surrounding the clot. Hematoma expansion in the first hours after onset is a major driver of poor outcome, which is why early BP control and coagulation correction are management priorities.
Clinical features
- Sudden onset of focal neurologic deficit (hemiparesis, hemisensory loss, aphasia, visual field cut) depending on location
- Headache, nausea, and vomiting more common than in ischemic stroke, reflecting raised intracranial pressure
- Decreased level of consciousness, which can progress over minutes to hours as the hematoma expands
- Seizures can occur, especially with lobar hemorrhages
- Hypertension at presentation is common
Location-specific clues
| Location | Classic features |
|---|---|
| Putamen/basal ganglia | Contralateral hemiparesis, hemisensory loss, gaze deviation toward lesion |
| Thalamus | Contralateral sensory loss often out of proportion to weakness, gaze palsy |
| Pons | Quadriparesis, pinpoint pupils, coma, abnormal respiratory pattern |
| Cerebellum | Ataxia, vomiting, occipital headache, risk of rapid deterioration from brainstem compression |
| Lobar | Seizures more common, deficit depends on lobe involved |
Diagnosis
Imaging
- Noncontrast CT head is the initial test of choice: hemorrhage appears hyperdense within minutes of onset, with high sensitivity.
- CT angiography can be added to look for an underlying vascular lesion (AVM, aneurysm) or a spot sign (contrast extravasation predicting hematoma expansion).
- MRI with susceptibility-weighted or gradient-echo sequences is more sensitive for microbleeds and is useful to evaluate for CAA (lobar microbleeds) or underlying tumor once the patient is stable.
Supporting workup
- Coagulation studies (PT/INR, aPTT, platelet count) to identify or reverse coagulopathy
- Blood glucose and metabolic panel
- Toxicology screen if sympathomimetic use is suspected, especially in younger patients
- Clinical severity and prognosis are often estimated using validated scores (e.g., the ICH Score), which incorporate GCS, hematoma volume, intraventricular extension, infratentorial origin, and age.
Differential diagnosis
- Acute ischemic stroke - cannot be reliably distinguished from ICH by clinical exam alone; CT is required
- Subarachnoid hemorrhage - typically thunderclap headache, blood in subarachnoid space/cisterns rather than parenchyma
- Subdural or epidural hematoma - usually associated with trauma, extra-axial blood on CT
- Hemorrhagic transformation of ischemic stroke - history of preceding infarct, often temporally related to thrombolysis
- Brain tumor with hemorrhage - look for surrounding mass, edema out of proportion, enhancement
- Hypoglycemia or other stroke mimics - check glucose promptly in any acute deficit
Management
Management is largely supportive and focused on limiting hematoma expansion and secondary injury; there is no drug that reverses the primary bleed itself.
Immediate measures
- Airway, breathing, circulation; intubate if GCS is low or airway protection is needed
- Admit to a neuro-ICU or stroke unit for close monitoring
- Blood pressure control: current guidelines (AHA/ASA) support rapid lowering of systolic BP to a target around 140 mmHg in appropriate patients, as this is generally safe and may reduce hematoma expansion; avoid overly aggressive drops that risk cerebral hypoperfusion
- Reverse anticoagulation promptly if the patient is on warfarin (prothrombin complex concentrate plus vitamin K) or on a direct oral anticoagulant (specific reversal agents or PCC depending on agent); hold antiplatelet/anticoagulant therapy
- Correct severe thrombocytopenia or coagulopathy as indicated
Intracranial pressure and surgical management
- Elevate head of bed, maintain normocapnia, consider osmotic therapy (mannitol or hypertonic saline) for signs of elevated ICP or herniation
- Surgical evacuation is generally reserved for specific scenarios: cerebellar hemorrhage with brainstem compression or hydrocephalus (often considered a neurosurgical emergency), and selected superficial lobar hemorrhages with mass effect and clinical deterioration
- Routine early surgical evacuation of supratentorial ICH has not shown consistent survival or functional benefit in major trials (e.g., STICH trials), so decisions are individualized
- External ventricular drain for hydrocephalus or significant intraventricular hemorrhage
- Seizure prophylaxis is not routinely recommended in the absence of clinical seizures; treat seizures if they occur
Longer-term
- Address underlying cause: strict long-term BP control, evaluate for vascular malformation, address anticoagulant indication versus bleeding risk before resuming
- Rehabilitation (physical, occupational, speech therapy) started as early as medically appropriate
- Decisions about resuming anticoagulation after ICH, especially lobar/CAA-related hemorrhage, require individualized risk-benefit discussion given high recurrence risk
Complications and prognosis
- Hematoma expansion (highest risk in first few hours)
- Elevated intracranial pressure and herniation
- Hydrocephalus from intraventricular extension
- Seizures, both acute and remote
- Perihematomal edema worsening over the first week
- Rebleeding, particularly with CAA (recurrent lobar hemorrhages)
- Long-term disability: many survivors have significant functional impairment
Prognosis depends heavily on hematoma volume, location (infratentorial worse), level of consciousness at presentation, patient age, and presence of intraventricular extension. ICH has substantially higher short-term mortality than ischemic stroke, with roughly a third of patients dying within the first month, though outcomes vary widely with these factors.
Think "PBTC" for classic hypertensive ICH locations: Putamen, Basal ganglia/thalamus, Thalamus, Cerebellum/pons — deep structures fed by small penetrating vessels.
Practice questions
1. A 68-year-old man with poorly controlled hypertension develops sudden right-sided weakness and slurred speech while gardening. On arrival, he is drowsy with a dense right hemiparesis and gaze deviation to the left. Noncontrast CT shows a hyperdense lesion in the left basal ganglia with surrounding edema. Which of the following is the most appropriate immediate step in management?
2. A 79-year-old woman with no history of hypertension presents with recurrent episodes of transient confusion and a new left arm weakness. MRI with susceptibility-weighted imaging shows multiple cortical and subcortical microbleeds along with a new lobar hemorrhage in the right parietal lobe. Which underlying process best explains these findings?
3. A 54-year-old woman develops sudden severe vertigo, vomiting, and inability to walk. Exam shows truncal and limb ataxia with nystagmus; she is awake but becomes progressively more somnolent over the next two hours. CT shows a 3.5 cm hemorrhage in the cerebellum with early effacement of the fourth ventricle. What is the most appropriate next step?
Frequently asked questions
What causes intracerebral hemorrhage?
The most common cause is chronic hypertension damaging small penetrating brain arteries, leading to rupture. Cerebral amyloid angiopathy is a leading cause in normotensive elderly patients and causes lobar bleeds. Other causes include anticoagulant use, vascular malformations, hemorrhagic transformation of a stroke, tumors, and sympathomimetic drugs like cocaine.
What are the first symptoms of intracerebral hemorrhage?
The first symptoms are usually sudden focal weakness or numbness on one side, often with headache, nausea, vomiting, and sometimes decreased alertness. Unlike many ischemic strokes, headache and vomiting are more common because of rising pressure inside the skull. Symptoms can worsen over minutes to hours as the bleed expands.
How is intracerebral hemorrhage diagnosed?
Diagnosis is made with a noncontrast CT scan of the head, which shows the blood as a bright (hyperdense) area within brain tissue, usually within minutes of symptom onset. CT angiography may be added to look for an underlying vascular cause or signs predicting further bleeding. MRI can help identify amyloid-related microbleeds or an underlying tumor once the patient is stable.
Is intracerebral hemorrhage curable?
There is no cure that reverses the bleed itself, but many patients survive with treatment focused on blood pressure control, reversing any anticoagulation, and preventing complications. Outcomes depend heavily on the size and location of the bleed and the patient's level of consciousness at presentation. Significant long-term disability is common among survivors, though some recover substantial function with rehabilitation.
Intracerebral hemorrhage vs ischemic stroke — what is the difference?
Intracerebral hemorrhage is bleeding into brain tissue, while ischemic stroke is loss of blood flow causing tissue death, usually from a clot. Both can cause identical sudden focal deficits, so they cannot be reliably told apart by symptoms alone; a CT scan is required. Treatment differs sharply, since clot-busting drugs used for ischemic stroke would worsen a hemorrhage.
Key drugs
Related conditions and differentials
Sources and further reading
StatPearls (NCBI Bookshelf)MedlinePlusWHO ICD-10: I61
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.